Morris MJ, et al. - This clinical practice guideline addresses abiraterone or docetaxel with androgen-deprivation therapy (ADT) for metastatic prostate cancer that has not been treated (or has been minimally treated) with testosterone-lowering agents. The efficacies of these treatment options were tested using results from three prospective randomized studies (GETUG-AFU 15, STAMPEDE, and CHAARTED). A survival benefit of ADT plus docetaxel or abiraterone vs ADT alone was seen in newly diagnosed metastatic non-castrate prostate cancer. Men with de novo high-volume (CHAARTED criteria) metastatic disease saw the strongest benefit with docetaxel. In high-risk patients (LATITUDE criteria) and the metastatic population in STAMPEDE, abiraterone acetate provided similar survival benefits. When deciding for ADT plus abiraterone or ADT plus docetaxel for men, fitness for chemotherapy, patient comorbidities, toxicity profiles, quality of life, drug availability, and cost should be considered.